Page 133 - CW E-Magazine (27-5-2025)

Top Stories Pharmaceuticals

FINANCIAL RESULTS IMPACT ASSESSMENT
Transport Corporation of India posts 11% increase in Q4 Generic fi rms unlikely to be impacted by US order

net profi t to cut prescription drug prices: Report

Transport Corporation of India Ltd. Net profi t for the full fi nancial year advancement. Driven by consumption Generic drug companies in India are Medicaid. The move follows Trump’s countries will be covered under the MFN
(TCI), a leading integrated multimodal FY2025 was at Rs. 4,161-crore – a rise lead warehousing demand, spanning not expected to be aff ected by US Presi- earlier statement that the government aims model. Offi cials are expected to inform
logistics and supply chain solutions of over 17% from Rs. 3,545-crore in quick commerce, retail and consumer dent Donald Trump’s new order to bring to cut the prices of prescription drugs by pharmaceutical companies about the target
provider, has reported net profi t of FY2024. durables sectors, we also strengthened the prices for prescription (Rx) drugs in 30-80 percent. This announcement came MFN prices within the next 30 days.
Rs. 115.1-crore for the fourth quarter our niche logistics and multimodal solu- line with other developed nations, accord- after the US Department of Health and
ended March 31, 2025 - a 11.4% increase Mr. Vineet Agarwal, MD, TCI, tions for bulk goods, heavy machinery ing to a report by HDFC Securities. Human Services (HHS) published a study The executive order also plans to by-
from Rs. 103.3-crore in the same year said, “FY2025 has been a year of and large equipment. As we look ahead, in February 2024, which showed that drug pass pharmacy benefi t managers (PBMs)
ago period. TCI reported a consolidated systemic growth at TCI. Despite global we are investing in up-skilling talent, The report stated that the order aims to prices in the US were signifi cantly higher by allowing American patients to pur-
revenue of Rs. 1,197.2-crore for Q4, uncertainties and evolving supply green logistics, automation and strategic reduce the cost of prescription medicines than those in other countries. chase medicines directly from manufac-
marking a growth of 9.3% compared chain dynamics, our focus on multi- partnerships, aligned with our vision to in the US by matching them with the prices turers at MFN prices. Other provisions
to Rs. 1,095.4-crore in the same period modal integration, sustainability and be a key enabler in positioning India as paid by other developed countries. It said, According to the report, the average include heavy discounts for low-income
last year. digitalisation have propelled decisive a global logistics hub”. “In our view, the generic companies are drug price in the US was 277 percent of patients on lifesaving drugs, importation
IFA appoints Nishant Kanodia of Matix Fertilisers to its Board unlikely to have any impact”. the international average. For branded programmes, and steps to boost the
drugs, the diff erence was even higher, US availability of generic and biosimilar
This executive order introduces the prices were 422 percent more than other medicines.
Mr. Nishant Kanodia, Promoter balanced nutrient management and “Most-Favoured-Nation (MFN)” price countries, and the top 60 brands were 504
and Chairman of Matix Fertilisers and innovation-driven growth has never been model. Under this model, the US will not percent costlier. In contrast, generic drug However, the report also mentioned
Chemicals Ltd., has been appointed greater. I look forward to supporting pay more for drugs than the lowest price prices in the US were only 67 percent of that the executive order is likely to face
to the Board of Directors of the Inter- IFA’s eff orts to empower farmers, pro- paid by other developed nations. the prices in other developed countries. legal hurdles. A similar MFN rule intro-
national Fertilizer Association (IFA), tect ecosystems, and enhance producti- duced in 2020-21 was blocked by courts.
a leading global body representing the vity globally and in India.” Earlier, this pricing model only applied Despite this, many details of the policy Still, the report believes that generic drug
entire fertiliser value chain. The appoint- to Medicare in 2020. Now, it has been remain unclear, the report noted. If is not companies are unlikely to be impacted by
ment was formalised at the IFA Annual Under Mr. Kanodia’s leadership, expanded to cover both Medicare and yet known which drugs, companies, or this policy.
Conference 2025 in Monaco. With Matix Fertilisers – an integrated crop
approximately 500 members across more nutrition company with revenues of GEARED FOR GROWTH
than 80 countries, IFA champions policy, around Rs. 7,000-crore – has established ‘Biocon’s businesses at a strong infl ection point’
innovation, and sustainable fertiliser itself as a market leader in Eastern India,
practices that contribute to global food with a 20% share of the region’s urea
security. market. Its facility in Panagarh, West Bengaluru-based Biocon said its The global GLP market is expected generics division posted strong 46 percent
a privilege to join the IFA Board at a Bengal, achieved a record production of businesses are at a promising infl ection to reach $130-135 billion by FY29, with growth, driven primarily by the supply of
Speaking on his induction to the time when India is increasingly central 1.47-million tonnes in FY25, operating point, with strong momentum expected even greater opportunities beyond that generic Lenalidomide in the US, along
IFA Board, Mr. Kanodia, said, “It is to global food security. The need for at over 115% of annual rated capacity. to continue. “We are at a stage where horizon. Peptide-based drugs such as with Dasatinib and Liraglutide in the UK.
all our business segments are positioned Semaglutide are expected to go off -pat- The biosimilars segment registered 9 per-
GPCA’s supply chain conference to begin from May 27 in Dubai for growth,” said Mr. Siddharth Mittal, ent in the US and Europe by 2031, and cent year-on-year growth, aided by new
CEO and Managing Director, Biocon. Tirzepatide (Monjaro) is set to follow launches in emerging markets, increased
The Gulf Petrochemicals and This year’s conference will fea- strategic opportunities. The conference The company reported a net profi t of after 2035, opening a large window for volumes of existing products, and market
Chemicals Association (GPCA) will ture keynote addresses, leadership dia- will conclude with a discussion explor- Rs. 344-crore in the March quarter, a biosimilar players like Biocon, Mr. Mittal share expansion in the US for three key
organise the 16th edition of its Supply logues, executive panel discussions, and ing the evolving landscape of global sup- 153 percent increase year-on-year. explained. In the near term, he highlighted biosimilars. The research services divi-
Chain Conference in Dubai, UAE case studies tackling various supply ply chains. GPCA will also host a special opportunities in Liraglutide, a drug cur- sion also saw 11 percent growth, attri-
on 27-28 May. Held under the theme chain challenges, including carbon foot- Gulf SQAS workshop on 26 May, explor- Mr. Mittal added that Biocon is pre- rently generating $2-bn in annual sales, buted to both research contracts and
“Building Resilience in a Dynamic print reduction and supply chain locali- ing the impact of Gulf SQAS on safety, paring to launch its products in several and Semaglutide in emerging markets, large molecule manufacturing.
Landscape,” the conference will ad- sation. Senior executives and industry sustainability, and operational excellence. new markets, including Europe, the US, which accounts for an additional $4-5
dress the critical challenges aff ecting leaders from the GCC chemical sector On 27 May, GPCA will celebrate the and other large emerging markets. “From billion in sales. The company’s board has approved
global and regional supply chains and will examine the fi ve key trends shaping achievements of companies and individuals a growth perspective, we see huge oppor- a fundraising plan to provide an exit for
highlight strategies for fortifying resi- 2025, providing perspectives into navi- at the 6th edition of the GPCA Supply tunities in the peptides or GLP (glucagon- Segment-wise growth some of its private equity investors. The
lience amid uncertainty. gating emerging risks and leveraging Chain Excellence Awards. like peptide) segment,” he said. On the business front, Biocon’s capital raise will be a combination of

132 Chemical Weekly May 27, 2025 Chemical Weekly May 27, 2025 133

Contents Index to Advertisers Index to Products Advertised